There is an urgent need for additional predictive biomarkers in NSCLC, as both PD-L1 and TMB are imperfect biomarkers with limited sensitivity and specificity for predicting ICI [5], which still suffer from biological and technical issues impacting standardisation and reproducibility [6–8]. Here, CD274 is linked to non-small cell lung carcinoma.